Ontology type: schema:ScholarlyArticle
2012-02-23
AUTHORSF. Petrelli, S. Barni, Anti-EGFR agents for liver metastases
ABSTRACTBackgroundCetuximab (C) and panitumumab (P) increase response rate and survival in KRAS wild-type metastatic colorectal cancer (mCRC). We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC.Materials and methodsWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for RCTs comparing first-line chemotherapy plus or minus C or P and reporting data in patients with KRAS wild-type, unresectable liver-limited mCRC. Relative risks (RRs) with 95% confidence interval were calculated. Meta-analysis of hazard ratios (HRs) for progression-free and overall survival (PFS and OS) was also performed.ResultsFour RCTs involving 484 KRAS wild-type patients were included. Compared to chemotherapy alone, the addition of C or P significantly increased the ORR (RR 1.67, p = 0.0001), the R0 resection rate from 11% to 18% (RR 1.59, p = 0.04) and PFS (HR 0.68, p = 0.002), but not OS (p = 0.42).ConclusionsThe addition of C and P increased the R0 resection rate by 60% and reduced the risk of progression by 32% in patients with mCRC and unresectable liver-limited disease. This combination represents one of the preferred choices as conversion therapy in KRAS wild-type patients with unresectable liver metastases. More... »
PAGES997-1004
http://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2
DOIhttp://dx.doi.org/10.1007/s00384-012-1438-2
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1046464035
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/22358385
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal, Humanized",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cetuximab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Colorectal Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "DNA Mutational Analysis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Disease-Free Survival",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "ErbB Receptors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Liver Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Panitumumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Proto-Oncogene Proteins",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Proto-Oncogene Proteins p21(ras)",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Publication Bias",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Randomized Controlled Trials as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risk",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "ras Proteins",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy",
"id": "http://www.grid.ac/institutes/grid.417270.7",
"name": [
"Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy"
],
"type": "Organization"
},
"familyName": "Petrelli",
"givenName": "F.",
"id": "sg:person.0661567716.40",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0661567716.40"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy",
"id": "http://www.grid.ac/institutes/grid.417270.7",
"name": [
"Medical Oncology Unit, Oncology department, Azienda Ospedaliera Treviglio Caravaggio, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy"
],
"type": "Organization"
},
"familyName": "Barni",
"givenName": "S.",
"id": "sg:person.0645550356.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645550356.01"
],
"type": "Person"
},
{
"familyName": "Anti-EGFR agents for liver metastases",
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.bjc.6605259",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048476579",
"https://doi.org/10.1038/sj.bjc.6605259"
],
"type": "CreativeWork"
}
],
"datePublished": "2012-02-23",
"datePublishedReg": "2012-02-23",
"description": "BackgroundCetuximab (C) and panitumumab (P) increase response rate and survival in KRAS wild-type metastatic colorectal cancer (mCRC). We performed a meta-analysis of randomised controlled trials (RCTs) to assess their effect on overall response rate (ORR), the rate of radical resection (R0) and survival in patients with liver-limited initially unresectable mCRC.Materials and methodsWe searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for RCTs comparing first-line chemotherapy plus or minus C or P and reporting data in patients with KRAS wild-type, unresectable liver-limited mCRC. Relative risks (RRs) with 95% confidence interval were calculated. Meta-analysis of hazard ratios (HRs) for progression-free and overall survival (PFS and OS) was also performed.ResultsFour RCTs involving 484 KRAS wild-type patients were included. Compared to chemotherapy alone, the addition of C or P significantly increased the ORR (RR 1.67, p\u2009=\u20090.0001), the R0 resection rate from 11% to 18% (RR 1.59, p\u2009=\u20090.04) and PFS (HR 0.68, p\u2009=\u20090.002), but not OS (p\u2009=\u20090.42).ConclusionsThe addition of C and P increased the R0 resection rate by 60% and reduced the risk of progression by 32% in patients with mCRC and unresectable liver-limited disease. This combination represents one of the preferred choices as conversion therapy in KRAS wild-type patients with unresectable liver metastases.",
"genre": "article",
"id": "sg:pub.10.1007/s00384-012-1438-2",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1096381",
"issn": [
"0179-1958",
"1432-1262"
],
"name": "International Journal of Colorectal Disease",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "8",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "27"
}
],
"keywords": [
"metastatic colorectal cancer",
"overall response rate",
"KRAS wild-type patients",
"R0 resection rate",
"wild-type patients",
"resection rate",
"hazard ratio",
"relative risk",
"KRAS wild-type metastatic colorectal cancer",
"liver-limited metastatic colorectal cancer",
"response rate",
"wild-type metastatic colorectal cancer",
"unresectable metastatic colorectal cancer",
"unresectable liver-limited disease",
"colorectal liver-limited metastases",
"liver-limited disease",
"liver-limited metastases",
"unresectable liver metastases",
"Cochrane Central Register",
"risk of progression",
"anti-EGFR agents",
"chemotherapy plus",
"ResultsFour RCTs",
"radical resection",
"Central Register",
"overall survival",
"liver metastases",
"Controlled Trials",
"colorectal cancer",
"patients",
"confidence intervals",
"conversion therapy",
"RCTs",
"survival",
"metastasis",
"trials",
"risk",
"ConclusionsThe addition",
"BackgroundCetuximab",
"resectability",
"panitumumab",
"resection",
"chemotherapy",
"EMBASE",
"MEDLINE",
"PFS",
"therapy",
"KRAS",
"cancer",
"MethodsWe",
"disease",
"progression",
"rate",
"outcomes",
"Register",
"OS",
"agents",
"interval",
"addition",
"Plus",
"effect",
"combination",
"data",
"ratio",
"choice",
"materials"
],
"name": "Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis",
"pagination": "997-1004",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1046464035"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00384-012-1438-2"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"22358385"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00384-012-1438-2",
"https://app.dimensions.ai/details/publication/pub.1046464035"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:00",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_581.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00384-012-1438-2"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00384-012-1438-2'
This table displays all metadata directly associated to this object as RDF triples.
214 TRIPLES
21 PREDICATES
110 URIs
101 LITERALS
25 BLANK NODES